EP1626717A4 - BENZIMIDAZOLES, COMPOSITIONS CONTAINING SAID COMPOUNDS AND METHODS OF USE - Google Patents

BENZIMIDAZOLES, COMPOSITIONS CONTAINING SAID COMPOUNDS AND METHODS OF USE

Info

Publication number
EP1626717A4
EP1626717A4 EP04751318A EP04751318A EP1626717A4 EP 1626717 A4 EP1626717 A4 EP 1626717A4 EP 04751318 A EP04751318 A EP 04751318A EP 04751318 A EP04751318 A EP 04751318A EP 1626717 A4 EP1626717 A4 EP 1626717A4
Authority
EP
European Patent Office
Prior art keywords
benzimidazoles
compounds
methods
compositions containing
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04751318A
Other languages
German (de)
French (fr)
Other versions
EP1626717A2 (en
Inventor
Emma R Parmee
Ronald M Kim
Rui Liang
Jiang Chang
Elizabeth Ashley Rouse
Kevin T Chapman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1626717A2 publication Critical patent/EP1626717A2/en
Publication of EP1626717A4 publication Critical patent/EP1626717A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP04751318A 2003-05-09 2004-05-05 BENZIMIDAZOLES, COMPOSITIONS CONTAINING SAID COMPOUNDS AND METHODS OF USE Withdrawn EP1626717A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46933203P 2003-05-09 2003-05-09
PCT/US2004/013874 WO2004100875A2 (en) 2003-05-09 2004-05-05 Benzimidazoles, compositions containing such compounds and methods of use

Publications (2)

Publication Number Publication Date
EP1626717A2 EP1626717A2 (en) 2006-02-22
EP1626717A4 true EP1626717A4 (en) 2009-09-09

Family

ID=33452275

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04751318A Withdrawn EP1626717A4 (en) 2003-05-09 2004-05-05 BENZIMIDAZOLES, COMPOSITIONS CONTAINING SAID COMPOUNDS AND METHODS OF USE

Country Status (6)

Country Link
EP (1) EP1626717A4 (en)
JP (1) JP2006528687A (en)
CN (1) CN1784226A (en)
AU (1) AU2004238240A1 (en)
CA (1) CA2524436A1 (en)
WO (1) WO2004100875A2 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572922B2 (en) 2003-01-27 2009-08-11 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
CA2540845C (en) * 2003-10-02 2010-11-09 Schering Corporation Aminobenzimidazoles as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
PT1756064E (en) * 2004-06-04 2008-07-22 Merck & Co Inc Pyrazole derivatives, compositions containing such compounds and methods of use
EP1773330B1 (en) 2004-07-22 2010-05-26 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
WO2007007910A1 (en) 2005-07-13 2007-01-18 Banyu Pharmaceutical Co., Ltd. Heterocycle-substituted benzimidazole derivative
EP1910303A2 (en) 2005-07-26 2008-04-16 Merck & Co., Inc. Process for synthesizing a substituted pyrazole
WO2007039177A2 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
TW200745031A (en) * 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
JP2010500300A (en) 2006-08-08 2010-01-07 サノフィ−アベンティス Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for their preparation, agents containing these compounds, and uses thereof
DE102007005045B4 (en) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazine derivatives, process for their preparation and their use as medicines
CN101610995B (en) 2007-02-09 2017-08-08 症变治疗公司 Glucagon Receptor Antagonists
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
BRPI0912245A2 (en) * 2008-03-05 2019-09-24 Takeda Pharmaceuticals Co compound, prodrug, drug, methods of suppressing sugar production in a mammal and for the prophylaxis or treatment of diabetes in a mammal, and use of the compound
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
US8907103B2 (en) 2008-08-13 2014-12-09 Metabasis Therapeutics, Inc. Glucagon antagonists
CN102361857B (en) * 2008-09-26 2015-09-16 默沙东公司 Can be used as the ring-type benzimidizole derivatives of antidiabetic
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
TWI475018B (en) * 2009-02-06 2015-03-01 Takeda Pharmaceutical Heterocyclic compound
RU2012111354A (en) 2009-08-26 2013-10-10 Санофи NEW CRYSTALLINE HYDRATES OF FLUORGYCLOSIDES CONTAINING THEIR PHARMACEUTICAL DRUGS AND THEIR USE
WO2011027849A1 (en) * 2009-09-04 2011-03-10 武田薬品工業株式会社 Heterocyclic compound
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
EP2582709B1 (en) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
BR112013016033A2 (en) 2010-12-23 2018-06-05 Pfizer glucagon receptor modulators
ES2597972T3 (en) 2011-02-08 2017-01-24 Pfizer Inc Glucagon receptor modulator
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683705B1 (en) 2011-03-08 2015-04-22 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683701B1 (en) 2011-03-08 2014-12-24 Sanofi Oxathiazine derivatives substituted with benzyl or heteromethylene groups, method for their preparation, their usage as medicament, medicament containing same and its use
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
EP2683703B1 (en) 2011-03-08 2015-05-27 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683702B1 (en) 2011-03-08 2014-12-24 Sanofi New substituted phenyl oxathiazine derivatives, method for their manufacture, medicines containing these compounds and their application
EP2683699B1 (en) 2011-03-08 2015-06-24 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
ES2550345T3 (en) 2011-07-22 2015-11-06 Pfizer Inc. Quinolinylglucagon receptor modulators
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
EP3752249A1 (en) 2018-02-13 2020-12-23 Ligand Pharmaceuticals, Inc. Glucagon receptor antagonists
CN112739365B (en) 2018-08-10 2025-10-28 糖平制药公司 Tripeptides and the treatment of metabolic, cardiovascular and inflammatory disorders
EP4656630A1 (en) * 2023-01-25 2025-12-03 Zymedi Co., Ltd. Novel compound as lysyl-trna synthetase 1 inhibitor, and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069810A1 (en) * 1999-05-17 2000-11-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
EP1069124A1 (en) * 1999-07-16 2001-01-17 Pfizer Inc. 2-Benzimidazolylamine compounds as ORL1-receptor agonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705515A (en) * 1994-04-26 1998-01-06 Merck & Co., Inc. Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069810A1 (en) * 1999-05-17 2000-11-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
EP1069124A1 (en) * 1999-07-16 2001-01-17 Pfizer Inc. 2-Benzimidazolylamine compounds as ORL1-receptor agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
R. M. KIM ET AL.: "Discovery of potent, orally active benzimidazole glucagon receptor antagonists", BIOORG. MED. CHEM. LETT., vol. 18, no. 13, 22 May 2008 (2008-05-22), pages 3701 - 3705, XP002537989 *

Also Published As

Publication number Publication date
CN1784226A (en) 2006-06-07
EP1626717A2 (en) 2006-02-22
JP2006528687A (en) 2006-12-21
WO2004100875A2 (en) 2004-11-25
CA2524436A1 (en) 2004-11-25
WO2004100875A3 (en) 2005-03-17
AU2004238240A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
EP1626717A4 (en) BENZIMIDAZOLES, COMPOSITIONS CONTAINING SAID COMPOUNDS AND METHODS OF USE
EP1699453A4 (en) CYCLIC GUANIDINES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE
EP1539730A4 (en) NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME
EP1668008A4 (en) NITROSIS AND NITROSYAL DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
EP2061476A4 (en) COMPOSITIONS CONTAINING CDP-CHOLINE AND METHODS OF USE THEREOF
EP1506786A4 (en) MEDICINAL COMPOSITIONS CONTAINING GHRELINE
EP1638977A4 (en) SALINOSPORAMIDES AND METHODS OF USE
EP1765379A4 (en) CO-CRISTAL PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
EP1569915A4 (en) SPIROCYCLIC UREAS, COMPOSITIONS CONTAINING SAME, AND METHODS OF USE
EP1603568A4 (en) ISOQUINOLINE DERIVATIVES AND METHODS OF USE
EP1670459A4 (en) NITROSIS AND NITROSYL CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE
EP1706791A4 (en) PHOTORESIN COMPOSITIONS AND METHODS OF USE
EP1636250A4 (en) SELF-ASSEMBLED PEPTIDES HAVING MODIFICATIONS AND METHODS OF USING PEPTIDES
FR2843023B1 (en) COSMETIC OR DERMOPHARMACEUTICAL COMPOSITIONS CONTAINING KOMBUCHA.
EP1831207A4 (en) AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF
EP1762234A4 (en) AMPK ACTIVATOR
EP1722797A4 (en) ISOQUINOLINE DERIVATIVES AND METHODS OF USE
EP1534683A4 (en) SELECTIVE INHIBITORS OF CYCLOOXYGENASE 2, COMPOSITIONS THEREOF AND METHODS OF USE
EP1851335A4 (en) COMPOSITIONS AND METHODS OF USING STANDARD MIXTURES
EP1624935A4 (en) ANTI-ADHERENCE COMPOSITES AND METHODS OF USING THE SAME
MA29030B1 (en) 2-ALCOXY-3,4,5-TRIHYDROXY-ALKYLAMIDES, PREPARATION THEREOF, COMPOSITIONS CONTAINING SAME AND USE THEREOF
EP1651231A4 (en) CYCLOALKANES DIPHENYL-SUBSTITUTES, COMPOSITIONS CONTAINING THESE COMPOUNDS, AND METHODS OF USE
EP1718621A4 (en) NITROXYL PRECURSOR COMPOUNDS AND METHODS OF USE
EP2376101A4 (en) Ss-ARRESTINE EFFECTORS, COMPOSITIONS CONTAINING SAME AND METHODS OF USE THEREOF
EP1633317A4 (en) LIGANDS OF SYNTHETIC CHEMKINIC RECEPTORS AND METHODS OF USE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051209

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: LT LV

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20051209

Extension state: LT

Payment date: 20051209

A4 Supplementary search report drawn up and despatched

Effective date: 20090806

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20091218